Arcturus Therapeutics Holdings Gestione
Gestione criteri di controllo 2/4
Arcturus Therapeutics Holdings Il CEO è Joe Payne, nominato in Mar2013, e ha un mandato di 11.67 anni. la retribuzione annua totale è $ 4.89M, composta da 14.3% di stipendio e 85.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.47% delle azioni della società, per un valore di $ 26.24M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 5.8 anni.
Informazioni chiave
Joe Payne
Amministratore delegato
US$4.9m
Compenso totale
| Percentuale dello stipendio del CEO | 14.3% |
| Mandato del CEO | 11.7yrs |
| Proprietà del CEO | 5.5% |
| Durata media del management | 1.5yrs |
| Durata media del Consiglio di amministrazione | 5.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$107m |
| Dec 31 2023 | US$5m | US$698k | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$3m | US$425k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$26m |
| Jun 30 2018 | n/a | n/a | -US$25m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$449k | US$384k | -US$11m |
Compensazione vs Mercato: La retribuzione totale di Joe ($USD 4.89M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.40M ).
Compensazione vs guadagni: La retribuzione di Joe è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Joe Payne (52 yo)
11.7yrs
Mandato
US$4,892,500
Compensazione
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 11.7yrs | US$4.89m | 5.47% $ 26.2m | |
| Founder | 11.8yrs | US$3.18m | 1.61% $ 7.7m | |
| CFO & Director | 6.3yrs | US$2.18m | 0.82% $ 3.9m | |
| Chief Legal Officer | 4.3yrs | US$2.10m | 0% $ 0 | |
| Vice President and Head of IR/PR & Marketing | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | 6.2yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 1.5yrs | Nessun dato | Nessun dato | |
| Chief Development Officer | 1.5yrs | Nessun dato | Nessun dato | |
| Chief Strategy Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Regulatory Officer | less than a year | Nessun dato | Nessun dato | |
| Controller | less than a year | Nessun dato | Nessun dato |
1.5yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di ARCT non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 11.7yrs | US$4.89m | 5.47% $ 26.2m | |
| CFO & Director | 5.2yrs | US$2.18m | 0.82% $ 3.9m | |
| Independent Chairman of the Board | 6.5yrs | US$328.00k | 0.36% $ 1.7m | |
| Independent Director | 5.2yrs | US$325.50k | 0.012% $ 55.5k | |
| Independent Director | 6.5yrs | US$330.50k | 0.049% $ 232.8k | |
| Independent Director | 6.5yrs | US$318.00k | 0.10% $ 497.7k | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 9.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 9yrs | Nessun dato | Nessun dato | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | Nessun dato | Nessun dato | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 2.7yrs | US$644.00k | Nessun dato | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | Nessun dato | Nessun dato |
5.8yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ARCT sono considerati esperti (durata media dell'incarico 5.8 anni).